These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 23527217)
1. Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. Nichols BE; Boucher CA; van Dijk JH; Thuma PE; Nouwen JL; Baltussen R; van de Wijgert J; Sloot PM; van de Vijver DA PLoS One; 2013; 8(3):e59549. PubMed ID: 23527217 [TBL] [Abstract][Full Text] [Related]
2. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. van de Vijver DA; Nichols BE; Abbas UL; Boucher CA; Cambiano V; Eaton JW; Glaubius R; Lythgoe K; Mellors J; Phillips A; Sigaloff KC; Hallett TB AIDS; 2013 Nov; 27(18):2943-51. PubMed ID: 23939237 [TBL] [Abstract][Full Text] [Related]
3. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice. Li J; Dufrene SL; Okulicz JF Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492 [TBL] [Abstract][Full Text] [Related]
4. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. Nichols BE; Baltussen R; van Dijk JH; Thuma PE; Nouwen JL; Boucher CA; van de Vijver DA J Acquir Immune Defic Syndr; 2014 Jun; 66(2):221-8. PubMed ID: 24694930 [TBL] [Abstract][Full Text] [Related]
6. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Plosker GL Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256 [TBL] [Abstract][Full Text] [Related]
7. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Krakower D; Mayer KH Ann Intern Med; 2012 Oct; 157(7):490-7. PubMed ID: 22821365 [TBL] [Abstract][Full Text] [Related]
8. Preexposure prophylaxis for the prevention of HIV transmission to women. Aaron E; Cohan D AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582 [TBL] [Abstract][Full Text] [Related]
9. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300 [TBL] [Abstract][Full Text] [Related]
10. Estimating HIV pre-exposure prophylaxis need and impact in Malawi, Mozambique and Zambia: A geospatial and risk-based analysis. Stelzle D; Godfrey-Faussett P; Jia C; Amiesimaka O; Mahy M; Castor D; Hodges-Mameletzis I; Chitembo L; Baggaley R; Dalal S PLoS Med; 2021 Jan; 18(1):e1003482. PubMed ID: 33428611 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ; HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684 [TBL] [Abstract][Full Text] [Related]
12. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? Baeten JM; Haberer JE; Liu AY; Sista N J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623 [TBL] [Abstract][Full Text] [Related]
13. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. Lehman DA; Baeten JM; McCoy CO; Weis JF; Peterson D; Mbara G; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Frenkel L; Ndase P; Mugo NR; Celum C; Overbaugh J; Matsen FA; J Infect Dis; 2015 Apr; 211(8):1211-8. PubMed ID: 25587020 [TBL] [Abstract][Full Text] [Related]
14. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries. Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512 [TBL] [Abstract][Full Text] [Related]
15. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402 [TBL] [Abstract][Full Text] [Related]
16. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM; Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446 [TBL] [Abstract][Full Text] [Related]
17. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition. de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466 [TBL] [Abstract][Full Text] [Related]
18. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. Liu A; Cohen S; Follansbee S; Cohan D; Weber S; Sachdev D; Buchbinder S PLoS Med; 2014 Mar; 11(3):e1001613. PubMed ID: 24595035 [TBL] [Abstract][Full Text] [Related]
19. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734 [TBL] [Abstract][Full Text] [Related]